Literature DB >> 24836189

Peptide-based cancer therapy: opportunity and challenge.

Dongdong Wu1, Yanfeng Gao2, Yuanming Qi3, Lixiang Chen2, Yuanfang Ma1, Yanzhang Li4.   

Abstract

Cancer is one of the leading causes of death worldwide. Conventional cancer therapies mainly focus on mass cell killing without high specificity and often cause severe side effects and toxicities. Peptides are a novel class of anticancer agents that could specifically target cancer cells with lower toxicity to normal tissues, which will offer new opportunities for cancer prevention and treatment. Anticancer peptides face several therapeutic challenges. In this review, we present the sources and mechanisms of anticancer peptides and further discuss modification strategies to improve the anticancer effects of bioactive peptides.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer mechanism; Cancer therapy; Modification strategy; Peptide

Mesh：

Substances：

Year:  2014        PMID： 24836189     DOI： 10.1016/j.canlet.2014.05.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  64 in total

Review 1.  Latarcins: versatile spider venom peptides.

Authors:  Peter V Dubovskii; Alexander A Vassilevski; Sergey A Kozlov; Alexey V Feofanov; Eugene V Grishin; Roman G Efremov
Journal:  Cell Mol Life Sci       Date:  2015-08-19       Impact factor: 9.261

2.  GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549).

Authors:  Kosar Hooshmand; Ahmad Asoodeh; Fatemeh Behnam-Rassouli
Journal:  Mol Cell Biochem       Date:  2016-10-04       Impact factor: 3.396

3.  Genetic engineering of platelets to neutralize circulating tumor cells.

Authors:  Jiahe Li; Charles C Sharkey; Brittany Wun; Jane L Liesveld; Michael R King
Journal:  J Control Release       Date:  2016-02-26       Impact factor: 9.776

4.  Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.

Authors:  Dongdong Wu; Wenke Tian; Jianmei Li; Qianqian Zhang; Honggang Wang; Lei Zhang; Zhongwen Xie; Ailing Ji; Yanzhang Li
Journal:  Mol Biol Rep       Date:  2019-04-26       Impact factor: 2.316

5.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

Review 6.  Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.

Authors:  Brizaida Oliva Arguelles; Mario Riera-Romo; Maribel Guerra Vallespi
Journal:  Br J Pharmacol       Date:  2020-06-21       Impact factor: 8.739

7.  Asp residues of βDELSEED-motif are required for peptide binding in the Escherichia coli ATP synthase.

Authors:  Zulfiqar Ahmad; Junior Tayou; Thomas F Laughlin
Journal:  Int J Biol Macromol       Date:  2015-01-17       Impact factor: 6.953

8.  A peptide interfering with the dimerization of oncogenic KITENIN protein and its stability suppresses colorectal tumour progression.

Authors:  Sung Jin Kim; Eun Gene Sun; Jeong A Bae; Sehoon Park; Chang-Soo Hong; Zee-Yong Park; Hangun Kim; Kyung Keun Kim
Journal:  Clin Transl Med       Date:  2022-07

9.  Venom peptides cathelicidin and lycotoxin cause strong inhibition of Escherichia coli ATP synthase.

Authors:  Sofiya Azim; Derek McDowell; Alec Cartagena; Ricky Rodriguez; Thomas F Laughlin; Zulfiqar Ahmad
Journal:  Int J Biol Macromol       Date:  2016-02-27       Impact factor: 6.953

10.  TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells.

Authors:  Jinfang Zhu; Weiran Liu; Chen Chen; Hua Zhang; Dongsheng Yue; Chenguang Li; Lianmin Zhang; Liuwei Gao; Yansong Huo; Chang Liu; Giuseppe Giaccone; Bin Zhang; Changli Wang
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-23       Impact factor: 4.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.